Anne S. Henkel, Sadiya S. Khan, Shantel Olivares, Toshio Miyata, Douglas E. Vaughan – 26 September 2018 – Plasminogen activator inhibitor 1 (PAI‐1), an essential regulator of fibrinolysis, is increasingly implicated in the pathogenesis of metabolic disorders, such as obesity and nonalcoholic fatty liver disease (NAFLD). Pharmacologic inhibition of PAI‐1 is emerging as a highly promising therapeutic strategy for obesity and its sequelae.

Marina Serper – 26 September 2018

Kara Walter, Christopher K. Johnson, Lena Sibulesky – 26 September 2018

Rahima A. Bhanji, Praveena Narayanan, Michael R. Moynagh, Naoki Takahashi, Mounika Angirekula, Cassie C. Kennedy, Kristin C. Mara, Ross A. Dierkhising, Kymberly D. Watt – 26 September 2018 – Sarcopenia and frailty are commonly encountered in patients with end‐stage liver disease and are associated with adverse clinical outcomes, including decompensation and wait‐list mortality. The impact of these entities in patients with differing disease etiologies has not been elucidated.

Christopher B. O’Brien, Eytan R. Barnea, Paul Martin, Cynthia Levy, Eden Sharabi, Kalyan R. Bhamidimarri, Eric Martin, Leopold Arosemena, Eugene R. Schiff – 26 September 2018 – Preimplantation factor (PIF) is an evolutionary conserved peptide secreted by viable embryos which promotes maternal tolerance without immune suppression. Synthetic PIF (sPIF) replicates native peptide activity. The aim of this study was to conduct the first‐in‐human trial of the safety, tolerability, and pharmacokinetics of sPIF in patients with autoimmune hepatitis (AIH).

Sander Lefere, Frederique Van de Velde, Anne Hoorens, Sarah Raevens, Sanne Van Campenhout, Astrid Vandierendonck, Sara Neyt, Bert Vandeghinste, Christian Vanhove, Charlotte Debbaut, Xavier Verhelst, Jo Van Dorpe, Christophe Van Steenkiste, Christophe Casteleyn, Bruno Lapauw, Hans Van Vlierberghe, Anja Geerts, Lindsey Devisscher – 26 September 2018 – Angiogenesis contributes to the development of nonalcoholic steatohepatitis (NASH) and promotes inflammation, fibrosis, and progression to hepatocellular carcinoma (HCC). Angiopoietin‐2 (Ang‐2) is a key regulator of angiogenesis.

Shi‐ying Cai, James L. Boyer – 25 September 2018

Alphonse E. Sirica, Gregory J. Gores, John D. Groopman, Florin M. Selaru, Mario Strazzabosco, Xin Wei Wang, Andrew X. Zhu – 25 September 2018 – Intrahepatic cholangiocarcinoma (iCCA) has over the last 10‐20 years become the focus of increasing concern, largely due to its rising incidence and high mortality rates worldwide.

David Goldberg, Raymond Lynch – 25 September 2018

Hannes Hagström, Jonas Höijer, Hanns‐Ulrich Marschall, Catherine Williamson, Michael A. Heneghan, Rachel H. Westbrook, Jonas F. Ludvigsson, Olof Stephansson – 25 September 2018 – There are limited data on pregnancy outcomes in women with cirrhosis. To address this gap, we examined the records of singleton births from Sweden’s National Patient Register (NPR), Cause of Death Register (CDR), and Medical Birth Register (MBR) between 1997 and 2011 to assess exposure and pregnancy‐related and liver‐related outcomes of pregnant women with cirrhosis.